Slovenian National COVID-19 Prevalence Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,000
- 试验地点
- 1
- 主要终点
- Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples
研究概览
简要总结
The investigators are conducting a national COVID-19 prevalence survey on a sample of 3,000 inhabitants that were randomly selected from the Slovenian population. The sample is representative in age, gender, and geographical distribution.
The main objective is to assess how many people in Slovenia have COVID-19 in April/May 2020 and how many were infected with SARS-CoV-2 previously.
The investigators are using a direct detection of SARS-CoV-2 RNA in nasopharyngeal samples with validated two-target PCR-based commercial assay. For a serological response to the etiological agent, IgG and IgA anti-SARS-CoV-2 antibodies are measured in plasma samples using a validated commercial assay.
详细描述
The investigators are conducting a national COVID-19 prevalence survey on a sample of 3,000 inhabitants that we have randomly selected from the Slovenian population. The sample is representative in age, gender, and geographical distribution.
The main objective is to assess how many people in Slovenia have COVID-19 in April/May 2020 and how many were infected with SARS-CoV-2 previously.
Direct detection of SARS-CoV-2 RNA in nasopharyngeal samples is performed with validated two-target PCR-based commercial assay. For a serological response to the etiological agent, IgG and IgA anti-SARS-CoV-2 antibodies are measured in plasma samples using a validated commercial assay.
Principal aims of the study are to systematically and accurately assess:
- How many people in Slovenia are actively infected with SARS CoV-2 in April/May 2020?
- How many are asymptomatic and do not even know they are or were infected?
- How many people in Slovenia have contacted SARS-CoV-2 and already have COVID-19 until mid May 2020?
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent only.
排除标准
- •Declined participation, no response on study invitation, no samples collected.
结局指标
主要结局
Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples
时间窗: April to May 2020
Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples
Prevalence of anti-SARS-CoV-2 antibodies in blood samples
时间窗: April to November 2020
Prevalence of anti-SARS-CoV-2 antibodies in blood samples
次要结局
未报告次要终点